Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.66 |
| ▸ | CTSK | P43235 | 5/20 | 0.66 |
| ▸ | REN | P00797 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801456 | 1.00 | CTSS (0.66) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL16417904 | 0.90 | CTSS (0.67) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL18401283 | 0.90 | CTSS (0.67) | CTSSCTSKCTSLCTSBACE | |
| SCHEMBL15344147 | 0.89 | CTSS (0.61) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL19575827 | 0.89 | REN (0.54) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL20661658 | 0.89 | REN (0.54) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL4710784 | 0.89 | REN (0.54) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL4710782 | 0.89 | REN (0.54) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL14975662 | 0.89 | REN (0.54) | CTSSCTSKRENCTSLCTSB | |
| SCHEMBL18227039 | 0.89 | REN (0.54) | CTSSCTSKRENCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1986694-B1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTHCARE AG (CH) | 2015-06-10 | — | — | EP | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | NOVO NORDISK HEALTH CARE AG (CH) | 2014-02-13 | — | — | US | disclosed |
| WO-2011011865-A1 | ANTICANCER AGENTS BASED ON AMINO ACID DERIVATIVES | 3R VALO, S.E.C. (CA) | 2011-02-03 | — | — | WO | disclosed |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | NOVO NORDISK A/S (DK) | 2010-05-06 | — | — | US | disclosed |
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | NOVO NORDISK HEALTH CARE AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| US-20070111926-A1 | Conjugation of peptides | NOVO NORDISK A/S (DK) | 2007-05-17 | — | — | US | disclosed |
| EP-1673464-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035553-A2 | CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2005-04-21 | — | — | WO | disclosed |
| US-6770740-B1 | PEPTIDE- DNA CARRIER COMPOSITIONS AND CONDENSED PARTICLES WITH REDUCED TOXICITY AND INCREASED STABILITY; USED IN COMBINATION WITH BIOCOMPATIBLE MATRICES, CARRIERS AND/OR TARGETING AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2004-08-03 | — | — | US | disclosed |
| CN-1143859-C | Camptothecin derivative and its preparation | ������ҩ��ʽ���� | 2004-03-31 | — | — | CN | disclosed |
| CN-1075501-C | Camptothecin derivatives, preparation method, intermediate and application | TANABE SEIYAKU CO (JP) | 2001-11-28 | — | — | CN | disclosed |
| CN-1308078-A | Camptothecin derivative and its preparation | TANADE SEIYAKU CO LTD (JP) | 2001-08-15 | — | — | CN | disclosed |
| WO-2001004135-A2 | CROSSLINKED DNA CONDENSATE COMPOSITIONS AND GENE DELIVERY METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105617-A1 | C-Terminal Attachment of Two Chemical Groups to Peptides | PTMS, DNPEP, VIP | CTSS 781/4885CTSK 660/4885REN 2096/4885 |
| US-20140045753-A1 | COUPLING OF POLYPEPTIDES AT THE C-TERMINUS | PTMS, VIP, LNPEP | CTSS 1145/4885CTSK 746/4885REN 2903/4885 |
| US-20100113747-A1 | Coupling of Antibody Polypeptides at the C-Terminus | FCGRT, FCGR3B, FCGR2A | CTSS 2465/4885CTSK 2108/4885REN 2533/4885 |
| US-20070111926-A1 | Conjugation of peptides | DNPEP, ENPEP, ANPEP | CTSS 248/4885CTSK 128/4885REN 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.